Hong Kong · Delayed Price · Currency is HKD Mega Genomics Statistics
Total Valuation
Mega Genomics has a market cap or net worth of HKD 1.54 billion. The enterprise value is 1.08 billion.
| Market Cap | 1.54B |
| Enterprise Value | 1.08B |
Important Dates
The next estimated earnings date is Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mega Genomics has 224.30 million shares outstanding. The number of shares has decreased by -4.81% in one year.
| Current Share Class | 224.30M |
| Shares Outstanding | 224.30M |
| Shares Change (YoY) | -4.81% |
| Shares Change (QoQ) | -6.83% |
| Owned by Insiders (%) | 22.89% |
| Owned by Institutions (%) | 0.01% |
| Float | 119.36M |
Valuation Ratios
The trailing PE ratio is 44.98.
| PE Ratio | 44.98 |
| Forward PE | n/a |
| PS Ratio | 5.59 |
| PB Ratio | 2.26 |
| P/TBV Ratio | 2.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.20, with an EV/FCF ratio of -58.25.
| EV / Earnings | 35.96 |
| EV / Sales | 3.93 |
| EV / EBITDA | 23.20 |
| EV / EBIT | 36.57 |
| EV / FCF | -58.25 |
Financial Position
The company has a current ratio of 3.64, with a Debt / Equity ratio of 0.05.
| Current Ratio | 3.64 |
| Quick Ratio | 3.31 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.70 |
| Debt / FCF | -1.76 |
| Interest Coverage | 19.45 |
Financial Efficiency
Return on equity (ROE) is 4.41% and return on invested capital (ROIC) is 10.83%.
| Return on Equity (ROE) | 4.41% |
| Return on Assets (ROA) | 2.11% |
| Return on Invested Capital (ROIC) | 10.83% |
| Return on Capital Employed (ROCE) | 4.20% |
| Weighted Average Cost of Capital (WACC) | 8.47% |
| Revenue Per Employee | 1.34M |
| Profits Per Employee | 145,967 |
| Employee Count | 206 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 5.89 |
Taxes
In the past 12 months, Mega Genomics has paid 6.46 million in taxes.
| Income Tax | 6.46M |
| Effective Tax Rate | 17.69% |
Stock Price Statistics
The stock price has decreased by -5.56% in the last 52 weeks. The beta is 0.79, so Mega Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -5.56% |
| 50-Day Moving Average | 7.13 |
| 200-Day Moving Average | 7.93 |
| Relative Strength Index (RSI) | 33.57 |
| Average Volume (20 Days) | 2,110 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mega Genomics had revenue of HKD 275.03 million and earned 30.07 million in profits. Earnings per share was 0.15.
| Revenue | 275.03M |
| Gross Profit | 130.60M |
| Operating Income | 29.57M |
| Pretax Income | 36.53M |
| Net Income | 30.07M |
| EBITDA | 39.84M |
| EBIT | 29.57M |
| Earnings Per Share (EPS) | 0.15 |
Balance Sheet
The company has 487.81 million in cash and 32.68 million in debt, with a net cash position of 455.13 million or 2.03 per share.
| Cash & Cash Equivalents | 487.81M |
| Total Debt | 32.68M |
| Net Cash | 455.13M |
| Net Cash Per Share | 2.03 |
| Equity (Book Value) | 679.86M |
| Book Value Per Share | 3.03 |
| Working Capital | 586.92M |
Cash Flow
In the last 12 months, operating cash flow was -18.39 million and capital expenditures -175,824, giving a free cash flow of -18.56 million.
| Operating Cash Flow | -18.39M |
| Capital Expenditures | -175,824 |
| Depreciation & Amortization | 10.64M |
| Net Borrowing | -10.53M |
| Free Cash Flow | -18.56M |
| FCF Per Share | -0.08 |
Margins
Gross margin is 47.49%, with operating and profit margins of 10.75% and 10.93%.
| Gross Margin | 47.49% |
| Operating Margin | 10.75% |
| Pretax Margin | 13.28% |
| Profit Margin | 10.93% |
| EBITDA Margin | 14.49% |
| EBIT Margin | 10.75% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.17, which amounts to a dividend yield of 2.52%.
| Dividend Per Share | 0.17 |
| Dividend Yield | 2.52% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 4.81% |
| Shareholder Yield | 7.34% |
| Earnings Yield | 1.96% |
| FCF Yield | -1.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mega Genomics has an Altman Z-Score of 5.89 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.89 |
| Piotroski F-Score | 4 |